Karyopharm Files for Chapter 11 to Sell Itself, With Gamida Cell Parent Ayrmid as Lead Bidder

What happened

Karyopharm Therapeutics, a cash-strapped cancer drugmaker, filed for Chapter 11 bankruptcy on Monday, Nov. 2, to sell the company and reorganize. According to BioPharma Dive, Ayrmid, the parent of cell therapy maker Gamida Cell, is the lead bidder in a court-supervised auction. The acquisition is expected to close in early 2027.

Karyopharm’s shares fell 83% to 11 cents after the announcement, giving the company a market value of about $2.5 million, BioPharma Dive reported.

Bankruptcy and deal details

• Process: A Chapter 11 filing with a court-supervised auction.
• Lead bidder: Ayrmid, parent of Gamida Cell. Bid terms were not disclosed in BioPharma Dive’s report.
• Financing: A $55 million bankruptcy loan from existing lenders to keep the business operating during the case.
• Debt pressure: About $15.8 million in debt is coming due; the company recently reached a forbearance agreement to delay payments.
• Timing: Closing expected in early 2027.

Ayrmid chief executive Joe Wiley said adding Xpovio could help “build a broader, stronger commercial-stage hematology business with meaningful opportunities for future growth.”

Company background

Karyopharm sells Xpovio, first approved in 2019 for multiple myeloma and later cleared for a common form of lymphoma. U.S. regulators could soon clear it for myelofibrosis, though a decision could take months, according to BioPharma Dive.

The company’s financial position deteriorated as sales failed to cover costs:

• Xpovio net sales were about $115 million in 2025.
• The company lost $196 million in 2025, and its accumulated deficit reached $1.8 billion.
• It held $55 million in cash and equivalents as of June 30, 2026.
• Xpovio failed a Phase 3 trial in endometrial cancer.

BioSpace also listed Karyopharm’s planned merger with Ayrmid among its latest deal headlines.

Why it matters for the sector

Karyopharm’s filing is a reminder that approval does not guarantee commercial viability. Companies that launch a drug in a crowded market and carry significant debt can struggle when sales grow more slowly than expected or when label expansions fail. Multiple myeloma, Xpovio’s original indication, has seen a wave of new therapies, including bispecific antibodies and CAR-T treatments, that have intensified competition.

Chapter 11 sales have become a recognized path for small commercial-stage biotechs that run out of options. A court-supervised auction can transfer an approved product to a buyer with a broader portfolio while clearing legacy debt, and a lead bidder sets a floor for competing offers.

For Ayrmid, the deal would add a marketed hematology product to Gamida Cell’s cell therapy business, consistent with Wiley’s description of building a broader commercial-stage hematology company. Acquiring an approved drug through bankruptcy can be less expensive than a conventional acquisition, though it requires navigating the court process and potential competing bids.

For shareholders, Chapter 11 cases involving companies with large accumulated deficits often leave little value for common stock once creditors are paid, which is reflected in the share price decline.

The case also highlights the role of lenders in biotech restructurings. Existing lenders providing debtor-in-possession financing often have significant influence over the sale process and the eventual outcome.

The outcome of the case will also be watched by other small commercial-stage biotechs with similar profiles, as well as by the lenders that finance them.

What to watch

• Bankruptcy court approval of bidding procedures and the auction timeline.
• Whether competing bidders emerge against Ayrmid.
• The FDA decision on Xpovio in myelofibrosis.
• Continuity of patient access to Xpovio during the case.

This article is for information only and is not investment advice.

Sources: BioPharma Dive, BioSpace

How a Chapter 11 Sale Process Works

Chapter 11 of the U.S. Bankruptcy Code lets a company continue operating while it restructures its obligations or sells its business under court supervision. When the goal is a sale, the process commonly unfolds in stages.

1. Filing and automatic stay. Filing the petition triggers an automatic stay, which generally pauses creditors’ efforts to collect debts or seize assets.
2. First-day motions. The company asks the court for permission to keep paying employees, maintain supplier relationships and use cash so operations continue.
3. Debtor-in-possession financing. A new loan, often from existing lenders, funds the business during the case. These loans typically receive priority over most other debts.
4. Stalking horse bid. A lead bidder signs an agreement that sets a minimum price and terms. In return, it may receive protections such as a breakup fee if outbid.
5. Bidding procedures and auction. The court approves rules for competing offers. If qualified bids arrive, an auction determines the highest or best offer.
6. Sale hearing. The court reviews and approves the winning bid. Sales under Section 363 of the Bankruptcy Code can transfer assets largely free of prior claims.
7. Distribution. Sale proceeds are distributed to creditors according to legal priority, and the remaining company is wound down or reorganized.

Who Gets Paid, and in What Order

Bankruptcy follows a general order of priority, sometimes called the waterfall:

• Secured creditors, such as lenders with claims on specific assets, are paid first from the value of their collateral.
• Administrative and priority claims, including costs of the case and certain employee and tax obligations, come next.
• Unsecured creditors, such as bondholders without collateral and many suppliers, share what remains.
• Equity holders receive value only if all creditors above them are paid in full.

That ordering explains why common shares in companies with large debts and accumulated losses often trade at very low prices once a filing is announced.

What Patients and Physicians Should Know

A Chapter 11 filing does not necessarily interrupt the supply of an approved medicine. Companies usually seek court approval to keep manufacturing, distribution and patient support programs running. Patients taking a medicine from a company in bankruptcy should continue to follow their physician’s guidance and can contact their pharmacy or the company’s patient support line with questions about supply.

Questions Readers Ask

What is a forbearance agreement?

An arrangement in which lenders agree temporarily not to enforce their rights after a missed payment or default, giving the borrower time to pursue a solution.

Can another bidder still win?

Yes. The purpose of a court-supervised auction is to test whether a better offer exists. The stalking horse bid sets the floor.

Why buy a drug through bankruptcy?

A buyer can acquire an approved product and its commercial operations without inheriting most legacy debts, often at a lower cost than a conventional acquisition.

This article is for general information only and is not legal, medical or investment advice.